Please login to the form below

Not currently logged in

Evotec enters new alliance with Genentech

Evotec and Genentech have formed a new integrated drug discovery alliance to support research into novel small molecule therapeutics

Evotec has announced today that it has formed a new alliance with Genentech (owned by Roche) to support Genentech's research to discover novel small molecule therapeutics.

Said Dr Werner Lanthaler, Evotec's CEO: "We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec's scientists and innovative drug discovery platform to support its research efforts. We look forward to working closely with Genentech's scientists and achieving success together."

The collaboration includes assay development and high throughput screening, medicinal chemistry and structural biology. Terms for the collaboration have not been disclosed.

Roche (one of several pharma companies working jointly with Evotec to develop its pipeline of products) already has several collaborative research areas in place, including one for product development in treatment-resistant depression and another to jointly discover and develop compounds against a target for CNS diseases and other indications.

Evotec is due to report its financial/performance results for the first quarter of 2010 on Wednesday May 12.

10th May 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...